Raymond James analyst Chris Raymond reiterated an Outperform rating and $910.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Regeneron submits U.S. application for gMG drug cemdisiranApril 21, 2026 10:30 AM Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 TrialApril 21, 2026 10:30 AM Regeneron Announces Investor Conference PresentationsApril 20, 2026 4:05 PM Goldman Sachs sees nearly 140% upside in this biopharma stockApril 20, 2026 7:30 AM